Heron Therapeutics (HRTX) 10-K2008 FY Annual report

Filed: 31 Mar 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: algorithm, appeal, ARB, assigned, authoritative, benchmark, Bonferroni, bound, breadth, Broadly, bruising, category, CI, conservation, CR, daily, dealing, defensive, deficiency, depletion, drawn, Emerging, entrenched, episode, eventual, Exparel, explicit, fell, fileable, filling, function, GAAP, Headache, headcount, hedge, hedged, hedging, Hesketh, hiring, identical, identity, implicit, IMS, inferior, infusion, intangible, John, joined, judge, Kevin, lieu, LLC, LP, maintenance, marketplace, mentioned, mitigated, moving, NI, notable, notification, NQ, NS, outweigh, overnight, Pacira, parent, patch, poly, predefined, Prentki, preserve, proactive, proportion, ProStrakan, purport, putting, qualitative, quantitative, quoted, radioactive, rational, reactivate, receptivity, reclassification, reject, renew, renewal, resumed, Ronald, Sancuso, sector, situation, slightly, statistically, stay, stratification, strength, structured, sublicensed, syringe, Tang, Task, temporarily, tier, transparency, undergone, underway, unprecedented, unused, variant, virtual, viscosity, waiver, Whelan, worker, workforce

Removed: acne, actinic, August, collectibility, concept, credited, fact, guidance, incorporate, Johnson, LLP, meloxicam, noncancelable, partial, plasma, post, prescribed, prescription, proof, reliably, remeasured, revalued, straight, surgery, unexercisable, variation, vest, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

HRTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of A.P. Pharma, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronald Prentki, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Ronald Prentki

Ronald Prentki

President and Chief Executive Officer

March 30, 2009

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of A.P. Pharma, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Whelan, Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ John Whelan

John Whelan

Vice President and Chief Financial Officer

March 30, 2009

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.